Literature DB >> 29376610

[The role of stress-induced chronic subclinical inflammation in the pathogenesis of the chronic pelvic pain syndrome IIIB in men].

I S Shormanov1, I I Mozhaev1, Kh A Sokolova1, A S Solovev1.   

Abstract

This literature review of recent clinical and experimental studies describes the role of oxidative stress in the multifactorial and interdisciplinary pathogenesis of non-inflammatory chronic pelvic pain syndrome IIIB (CPPS-IIIB) in men. The authors outline general biological nature of oxidative stress and its mechanisms. More detailed information is presented on cytokine-mediated chronic subclinical inflammation, one of the key mechanisms of oxidative stress, which is currently being actively studied. It is shown that the imbalance between pro- and anti-inflammatory cytokines observed in patients with CPPS-IIIB can explain some features of the clinical course (in particular, the characteristics of the pain syndrome) and the progression of this disease. In this regard, cytokine profiling of prostatic secretion can provide valuable diagnostic, prognostic and monitoring information in the management of this category of patients. Recently published evidence has demonstrated the essential role of the cytokine-mediated chronic inflammatory response as a mechanism of oxidative stress in the pathogenesis of CPPS-IIIB. Further studies in this area are warranted and in the long term may become a basis for the development of new effective pathogenetic pharmacotherapy of CPPS-IIIB.

Entities:  

Keywords:  chronic pelvic pain syndrome IIIB; chronic subclinical inflammation; cytokines; interleukins; oxidative stress; pathogenesis

Mesh:

Year:  2017        PMID: 29376610

Source DB:  PubMed          Journal:  Urologiia        ISSN: 1728-2985


  1 in total

1.  Targeting Ferroptosis Attenuates Inflammation, Fibrosis, and Mast Cell Activation in Chronic Prostatitis.

Authors:  Dongxu Lin; Mengyang Zhang; Changcheng Luo; Pengyu Wei; Kai Cui; Zhong Chen
Journal:  J Immunol Res       Date:  2022-06-17       Impact factor: 4.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.